KR20220151265A - Nasal drug dispensing device and method - Google Patents

Abstract

The present invention provides a nasal cavity and nasopharyngeal drug injection device in which a drug storage container and a pressure generating device are combined, the end of a straight passage of a nozzle pipe is closed, an injection hole is formed on the side of the nozzle pipe, and a nozzle is mounted, wherein the nozzle pipe is made of any one or a combination of silicone, rubber vinyl, plastic, or stainless steel. The present invention provides a device and a method for preventing or treating respiratory infections by enabling a patient to administer drug in the nasal cavity and the nasopharynx by himself or herself. In particular, provided is a nasal and nasopharyngeal drug administration device and a method thereof which are effective for preventing or treating a cold, influenza, and COVID-19.

Description

Nasal drug dispensing device and method {Nasal drug dispensing device and method}

The present invention relates to a device and method capable of injecting a drug into the nasal cavity, and more particularly, to a device and method for delivering a drug to the nasal cavity and the nasopharynx outside the posterior nares, particularly to the ceiling of the nasopharynx and the wall of the nasopharynx. Through this, an apparatus and method capable of removing infectious agents such as viruses or bacteria inhabiting the mucous membranes of the nasal cavity and nasopharynx are provided.

Air inhaled through the nostrils passes through the nasal cavity and reaches the nasopharynx outside the posterior nostril. At this time, most of the particles in the air, including bacteria and viruses that have passed through the nasal cavity, adhere to the mucous membrane of the nasopharynx and invade the mucous membrane, causing infection and inflammation. As long as a person breathes through the nose, these infections always exist, and thus many kinds of pathogens such as viruses and bacteria cause infections in the nasal cavity and nasopharynx. In order to prevent or treat respiratory infections, pathogens that cause infections in the nasal cavity and nasopharynx must be eliminated before lower respiratory tract infections lead to pneumonia.

A vaccine has been developed for Covid-19, which occurred in 2019, causing numerous deaths and causing a pandemic while still terrifying people around the world, but it is too short to inoculate people around the world, so when will it form antibodies to all mankind? An unknown situation continues. A bigger problem is that it is not known how long the duration of antibodies produced by vaccination will last. Experts predict that the duration of antibodies is short, so annual vaccinations will be required. Meanwhile, the more depressing news is that emerging mutant viruses are becoming resistant to current vaccines. Thus, it remains unknown when current vaccines will be incapacitated.

In addition to COVID-19, there are more than 200 viruses that cause respiratory infections. The most common disease, the common cold, is reported in more than 1 billion cases annually in the United States alone. The CDC reports that during the 2019-2020 influenza season, more than 26 million Americans contracted influenza, 250,000 were hospitalized, and 14,000 died. The World Health Organization (WHO) estimates seasonal flu causes between 250,000 and 500,000 deaths worldwide each year.

Most patients who die from respiratory viruses, including COVID-19, die of pneumonia. Pneumonia does not occur because the virus enters the lungs in the first place. There are few viral receptors in the lungs, so infection is less likely to occur. Nevertheless, lung infection occurs because the virus first infects the nasal cavity, replicates the viruses, and combines the progeny viruses produced in this way with the progeny viruses produced in the nasopharynx, continuously spraying progeny viruses from the nasopharynx to the lungs. because it gives

Thus, respiratory infectious viral diseases, especially COVID-19, are detected in higher amounts in the nasal cavity and nasopharynx than in the throat. This is because there are many viruses in the nasopharyngeal mucosa. Therefore, mucus is collected from the nasopharynx to check for COVID-19 infection. In addition, the greater the amount of virus detected in the nasopharynx, the more severe the symptoms and the higher the mortality rate.

As such, the amount of virus in the nasal cavity and nasopharynx has a very important meaning. Even in patients with mild symptoms, the higher the amount of virus in the nasal cavity and nasopharynx, the worse the condition becomes. Conversely, reducing the amount of virus in the nasal cavity and nasopharynx reduces symptoms and lowers mortality. Thus, reducing the amount of nasal and nasopharyngeal viruses reduces the severity of COVID-19 disease. The case of influenza is the same.

As such, the amount of virus in the nasal cavity and nasopharynx is very important. In particular, the amount of virus in the nasopharynx is important. However, until now, there is no known method for eradicating or reducing the amount of viruses in the nasopharynx. The nasopharynx is located at the deepest back of the nasal cavity behind the posterior nostril and behind the uvula, making it very difficult to access and difficult to deliver drugs. It is possible to send a vapor or mist through the nostrils, but it is difficult to administer a sufficient amount of the drug to be effective. Thus, there is a need for new means capable of delivering a sufficient amount of drug to the nasopharynx.

For example, even though the COVID-19 virus causes serious illness, the initial symptoms are mild, so people infected with it think it's a mild cold and spend their time hoping that it will get better on its own without going to expensive hospitals. Unfortunately, however, viruses replicate rapidly during this asymptomatic period, leading to serious illness. Therefore, if a viral infection occurs in the respiratory tract, prompt treatment is very important. The virus must be eradicated as early and as quickly as possible. Even in the absence of symptoms, if treatment is delayed, the infection progresses rapidly, causing extensive tissue damage, making treatment more difficult. Therefore, when the patient is asymptomatic or mildly symptomatic, the patient must be able to quickly treat the disease without expensive equipment and without temporal and spatial limitations. In particular, there should be a convenient device for administering drugs to the nasopharynx. There is an urgent need for a convenient device for administering drugs to the nasopharynx by the patient himself.

US6238377B1 US10179216B2 US 2018/0256867

It is an object of the present invention to provide a device and method for delivering a sufficient amount of drug to the walls of the nasopharynx, including the nasal cavity and nasopharynx, particularly the nasopharyngeal roof. There is a nasopharyngeal tonsil that is sensitive to infections in the nasopharyngeal ceiling, and a good effect can be obtained only when sufficient drug is delivered to the nasopharyngeal ceiling. Conventionally, a device called Nasalpharygeal wash has been known, but this device is not a device for administering drugs to the nasopharynx. It is a device used to suck mucus from the nasopharynx and test for viruses. Inability to administer a sufficient amount of drug to the nasal cavity and nasopharyngeal surfaces, including the nasopharyngeal roof.

The present invention provides a novel nasal cavity and nasopharyngeal drug delivery device and method capable of administering drugs from the nasal cavity and nasopharyngeal ceiling to the upper surface of the soft palate and the upper, lower, left, and right nasopharyngeal walls.

Nasal and nasopharyngeal drug delivery devices including; A device for spraying drugs into the nasal cavity and the nasopharynx by being inserted into the nasal cavity, comprising: a nozzle tube having a passage through which drugs pass; The end of the straight passage of the nozzle pipe is closed, and the spray hole is formed on the side of the nozzle pipe; The material of the nozzle tube is to mount a nozzle made of any one of silicone, rubber vinyl, plastic, or stainless steel, or a combination thereof, and a drug storage unit to be sprayed, and a drug so that the stored drug can be sprayed into the nasopharynx through the nozzle tube. It is composed of a pressure generator capable of applying pressure to provide a device and method for administering drugs to the nasal cavity and nasopharynx by the patient himself.

The nasal cavity and nasopharyngeal drug administration device of the present invention according to the above solution enables drug administration to a wide range of sites in the nasopharynx, including the nasal cavity and the nasopharyngeal roof behind the nasal cavity.

When the device for administering drugs to the nasal cavity and nasopharynx is implemented in this way, the drug is delivered to the entire upper respiratory tract very conveniently and conveniently, and the drug is sufficiently delivered to the wide surface of the nasal cavity and nasopharynx to effectively inhibit viruses and bacteria inhabiting the mucous membrane of the upper respiratory tract. can be activated. This convenience can be effective in preventing and treating time-sensitive acute respiratory viral infections, especially COVID-19.

Thus, the device and method for administering nasal and nasopharyngeal drugs of the present invention are effective in preventing and treating not only the common cold, but also influenza, SARS, MERS, and new viral infectious diseases.

In particular, the device and method for administering drugs to the nasal cavity and nasopharynx of the present invention allow the patient to administer drugs to the nasopharynx, which is difficult to access without anesthesia by a doctor or an expensive nebulizer device, or to clean the nasopharynx, etc. It provides a simple and convenient means to prevent or treat acute respiratory infections while saving time and money by administering drugs.

In order that the present invention may be more fully understood and its objects and advantages made clear, reference is made to the detailed description of preferred embodiments shown in the accompanying drawings below.
The accompanying drawings are not necessarily drawn to scale, and like drawings may depict substantially similar components throughout several like drawings. The drawings generally illustrate, but are not to be construed as limiting, details of specific embodiments discussed herein.
1 is a nozzle model diagram of an embodiment of the present invention.
Schematic diagram of a nozzle with a passage inside for the drug to be administered to pass through, a closed straight end, and a nozzle on the side for dispensing the drug that has penetrated to the outside.
Fig. 2 is a schematic view of the nozzle outlined in Fig. 1, in which an end flange is constructed to prevent the nozzle from slipping out of the device and into the nasal cavity when pressure is generated.
3 is a schematic view of a nozzle having a flange installed so that the flange of the nozzle unit outlined in FIG. 2 coincides with the direction of the injection port so that the direction of drug injection into the nasopharynx can be known.
Figure 4 is an exemplary view showing a drug injection hole formed on the side of the nozzle of Figures 1 to 3;
Figure 5 is a schematic view of the nasal cavity and nasopharyngeal drug injection syringe device equipped with a drug injection nozzle.
Figure 6 is a drug injection example showing the shape of the drug is injected from the nozzle of the nasal cavity and nasopharyngeal drug injection device of Figure 5;
Figure 7 is a syringe drug injection example showing a shape in which a plurality of water streams of drug are injected from the nozzle of the device of Figure 5;
Figure 8 is a syringe drug injection example showing a shape in which a plurality of water streams of drug are injected in a wide direction from the nozzle of the device of Figure 5;
Figure 9 is an exemplary view of a spray ice and nasopharyngeal drug spray device in which the nozzles of FIGS. 1 to 3 are attached to the spray device.
Figure 10 is an exemplary view of nasopharyngeal drug injection in which the drug is injected into the nasopharynx by inserting a nozzle into the nasal cavity.

The present invention refers to the accompanying drawings in the detailed description of the following embodiments.

By way of example, the present invention may be practiced according to specific embodiments. Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.

The material of the nozzle is preferably made of a soft material. If the material is rough, it can cause irritation when inserted into the nasal cavity. So silicone, rubber, vinyl, plastic or smooth stainless steel materials are good. In addition, if the material is too soft, it can be severely bent and difficult to insert into the nasal cavity. In this case, a stainless steel injection needle with a blunt tip can be inserted into the nozzle to reduce irritation and prevent bending.

See Figure 1. 1 illustrates a nasal cavity and nasopharyngeal drug injection nozzle according to an embodiment of the present invention. One end of the nozzle is connected to a drug reservoir and the reservoir is in turn connected to a pressure generating device. For example, in combination with a syringe, spray device or other form of drug storage and pressure device.

Figure 5 shows one embodiment to be considered in order to carry out the present invention, the injection pressure producing unit is connected to the storage container for receiving the drug solution or fluid to be administered through the device of the present invention, the nozzle is a drug storage and pressure It is shown as installed in connection with the production unit. The pressure generated by the pressure generating unit causes the chemical solution or fluid stored in the storage container to be sprayed through the injection hole of the nozzle.

In order to spray the drug into the nasal cavity and nasopharynx, a pressurizing device is required because the drug must be sprayed by applying pressure to the drug. A syringe, spray device or various pressure generating devices may be employed for this purpose. Conveniently, a syringe or spray device is good.

The length of the nozzle should be greater than the length from the nostril entrance to the nasopharynx. This length varies from person to person, but in the case of children, it is within 10 cm, and in the case of adults, it is approximately 10 cm or more, and the size is 20 cm. Therefore, the length of the nozzle is appropriately 10 cm to 20 cm long.

The outer diameter of the nozzle should not be too large to facilitate nasal insertion. For example, it is better not to exceed 10 mm. Preferably, the outer diameter does not exceed 8 mm. In addition, the inner diameter of the nozzle through which the drug passes is within 5 mm, preferably 1 mm to 3 mm.

In the example of FIG. 4 , one end of the nozzle in the linear axial direction is closed, and injection holes may be disposed on the side of the nozzle on the closed side. A nozzle head portion where the injection hole is disposed may be larger than a nozzle tube portion and may be formed in an elliptical shape. The height diameter of the elliptical nozzle head portion may be 4 mm to 10 mm and the width of the elliptical nozzle head portion may be 3 mm to 6 mm.

One or more injection holes may be disposed, and up to 50 may be installed. Preferably, 5 to 20 are suitable. An injection hole is installed on the side of the distal end of the nozzle, and the drug is injected to the wall of the nasopharynx through the injection hole. The injection hole is preferably disposed on the upper side of the nozzle. The injection hole is preferably disposed within a distance of 5 cm from the tip of the nozzle. 1 to 50 spray holes may be disposed, but preferably 2 to 10 are good. In addition, since it should be sprayed on a wide area of the nasopharynx, the wider the spray angle, the better. It is preferable that the interior angle is widely sprayed between 45 degrees and 150 degrees from the nozzle central linear axis.

The injection hole is preferably disposed so that the injection can be performed in the nasal cavity, the posterior nares, and the nasopharyngeal ceiling where the nasopharyngeal tonsil is located as a target to which the drug is to be administered. The position of the injection hole is within 10 cm, preferably within 5 cm, more preferably within 3 cm from the end of the nozzle.

An object of the present invention is to provide a device and method for preventing or treating diseases of the nasal cavity and nasopharynx. In order to achieve the above object, the device of the present invention should inject the drug from the nasal cavity to the ceiling of the nasopharynx, the left and right side walls of the nasopharynx, and the posterior wall. To this end, the nozzle is injected while inserting the nozzle from the entrance to the nasal cavity to the tip of the nasopharynx, and at the same time, the nozzle is moved little by little to spray the drug so that it evenly reaches the large area of the nasal cavity and nasopharynx.

The device of the present invention makes it possible to spray the drug into the nasal cavity and into the nasopharynx, which is an area that is difficult to access easily. A long, smooth, multi-orifice nozzle makes this possible.

The device for administering nasal and nasopharyngeal drugs of the present invention makes it possible to administer all kinds of drugs including saline solution, antiseptic, antiviral, antibiotic, antifungal, vaccine, or all kinds of drugs usable for preventing and treating diseases of the nasal cavity and nasopharynx.

In one embodiment, the drug that can be sprayed into the nasal cavity and nasopharynx using the device of the present invention is a solution containing 0.9 w/v% to 5 w/v% sodium chloride, and the disinfectant is povidone iodine 0.01 w/v% to 1 w/v%. containing solutions, preferably solutions containing 0.9 w/v% to 3 w/v% of sodium chloride and 0.1 w/v% to 0.5 w/v% of povidone iodine. More preferably, a solution containing 0.9 w/v% to 2 w/v% of sodium chloride and 0.1 w/v% to 0.3 w/v% of povidone iodine is preferable.

In one embodiment, nasal and nasopharyngeal drug administration devices and methods are useful for preventing or treating cold virus infectious diseases.

In one embodiment, nasal and nasopharyngeal drug administration devices and methods are capable of preventing or treating influenza virus infections. A solution containing 0.9 w/v% to 2 w/v% of sodium chloride and 0.2 w/v% to 0.45 w/v% of povidone iodine may be used.

In one embodiment, the device and method for administering nasal and nasopharyngeal drugs can be used to prevent or treat COVID-19 viral infection disease. A solution containing 0.9 w/v% to 2 w/v% of sodium chloride and 0.1 w/v% to 0.3 w/v% of povidone iodine may be used.

The nasal and nasopharyngeal drug administration device and method of the present invention can administer a fluid, liquid or droplet of gel or gel paste or any material that can be expelled to the nasal cavity and nasopharynx.

The device and method for administering nasal and nasopharyngeal drugs of the present invention are used in the prevention and treatment of a number of nasal and nasopharyngeal infectious diseases or respiratory infections, such as influenza and SARS, MERS and new viruses, as well as common colds, by the following methods can be applied

Example 1

Nasal and nasopharyngeal irrigation

Fill the syringe with 20 ml of physiological saline, attach a silicone nozzle with 6 injection holes and a length of 130 mm, and then start injection by pushing the syringe pusher while slowly pushing the nozzle into the nasal cavity. Continue spraying by slowly pushing the nozzle in until the tip of the nozzle touches the wall of the nasopharynx. When spraying, move the nozzle little by little so that the tip of the nozzle fluctuates instead of being fixed, so that the spraying range is widened. Inject 20ml into each nostril and 20ml into the nasopharynx. Discard the solution that flows out during spraying and spit it out if it goes down your throat.

Example 2

Common cold prevention and treatment

The same procedure as in Example 1 was performed using a solution containing 0.9 w/v% of sodium chloride and 0.2 w/v% of povidone iodine instead of the physiological saline solution of Example 1.

Example 3

Influenza prevention and treatment

The same procedure as in Example 1 was performed using a solution containing 1.5 w/v% of sodium chloride and 0.2 w/v% of povidone iodine instead of the physiological saline solution of Example 1.

Example 4

The same procedure as in Example 1 was performed using a solution containing 1.5 w/v% of sodium chloride and 0.25 w/v% of povidone iodine instead of the physiological saline solution of Example 1.

Example 5

The same procedure as in Example 1 was performed using a solution containing 0.9 w/v% of sodium chloride and 0.45 w/v% of povidone iodine instead of the physiological saline solution of Example 1.

Example 6

The same procedure as in Example 1 was performed using a solution containing 1.5 w/v% of sodium chloride and 0.45 w/v% of povidone iodine instead of the physiological saline solution of Example 1.

Example 7

A person with COVID-19, with or without symptoms, immediately after confirmation of infection

Instead of the physiological saline solution of Example 1, a solution containing 1.5 w/v% of sodium chloride and 0.23 w/v% of povidone iodine was disinfected and washed for 30 seconds each in the same manner as in Example 1, and the laryngeal spray was inhaled with 10 ml of the solution. and 30 ml. Uninfected twice a day for 30 seconds each

Continue until confirmed.

The detailed description of various embodiments of the present invention is provided by way of example only, and various changes and modifications may be made without limiting the scope of the present invention.

The present invention provides a drug delivery device and method capable of overcoming the limitations of conventional prevention and treatment of nasal and nasopharyngeal diseases and administering drugs from the nasal cavity to the ceiling of the nasopharynx and the wall of the nasopharynx by the patient himself. In one embodiment, the device of the present invention provides a device and method for preventing or treating acute respiratory infections by injecting a drug by a patient himself.

Claims (8)

In the device for injecting drugs into the nasal cavity and nasopharynx through the nostrils,
The material of the nozzle mounted on the device and spraying the drug is silicone, rubber, vinyl or plastic;
One end of the drug passage inside the nozzle is closed;
A spray hole is placed within 5 cm of the closed end;
1 to 50 injection holes are arranged on the side;
and
The size of the injection hole is 0.01mm to 2mm;
Nasal cavity and nasopharyngeal drug injection device, characterized in that the nozzle is mounted. According to claim 1,
The drug storage and pressure generating device is a syringe or spray-in device, the material is silicone, and a nozzle having 2 to 10 injection holes having a size of 0.05 mm to 1 mm is mounted on the side of the nasal cavity and nasopharyngeal drug injection. Device. According to claim 1,
A nasal cavity and nasopharyngeal drug injection device characterized in that a blunt stainless steel injection needle is inserted into the nozzle tube and mounted on the syringe. According to claim 1,
The length of the nozzle is 5 cm to 20 cm,
The outer diameter of the nozzle is 3 mm to 8 mm,
The inner diameter of the nozzle tube is 0.5 mm to 2 mm,
Nasal cavity and nasopharyngeal drug spray device, characterized in that the nozzle tube is equipped with a nozzle having a thickness of 0.1 mm to 2 mm. According to claim 1,
Nasal cavity and nasopharyngeal drug injection device, characterized in that there are 4 to 8 injection holes on the side of the nozzle, and the size of the injection holes is 0.01 mm to 0.8 mm. According to claim 1,
The length of the nozzle tube is 10 cm to 15 cm, the outer diameter of the nozzle tube is 3 mm to 7 mm, there are 4 to 8 drug injection holes on the side of the nozzle tube, and the size of the injection holes is 0.01 mm to 1 mm. A silicone nozzle is attached to the syringe. Nasal cavity and nasopharyngeal drug injection device, characterized in that one. A nozzle mounted on the nasal cavity and nasopharyngeal drug injection device according to any one of claims 1 to 6, with a length of 5 cm to 20 cm, an outer diameter of 3 mm to 7 mm, and 1 to 50 drug injection holes on the side, , The size of the injection hole is 0.01mm to 1mm, a nasal injection drug injection nozzle made of silicone, rubber, vinyl or plastic material. A composition for use with the nasopharyngeal drug injector device of claim 1;
The composition is a nasal and nasopharyngeal administration composition containing 0.9 w / v% to 3 w / v% of sodium chloride and 0.1 w / v% to 0.5 w / v% of povidone iodine.

Images